Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $25.75

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have been assigned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.75.

Several equities analysts recently commented on OCUL shares. Robert W. Baird increased their target price on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Chardan Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of Ocular Therapeutix in a report on Tuesday, August 4th. Finally, Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $10.78 on Friday. The business has a 50-day simple moving average of $9.57 and a 200-day simple moving average of $9.12. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. Ocular Therapeutix has a one year low of $6.23 and a one year high of $16.44. The company has a market cap of $2.37 billion, a PE ratio of -7.59 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company had revenue of $13.47 million during the quarter, compared to the consensus estimate of $13.20 million. During the same quarter in the previous year, the firm earned ($0.39) earnings per share. The firm’s quarterly revenue was down .1% on a year-over-year basis. On average, equities research analysts forecast that Ocular Therapeutix will post -1.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC increased its position in shares of Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in Ocular Therapeutix during the 4th quarter worth approximately $31,000. Hilton Head Capital Partners LLC acquired a new position in Ocular Therapeutix during the fourth quarter worth approximately $42,000. Atlas Capital Advisors Inc. purchased a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $61,000. Finally, State of Wyoming purchased a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $78,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.